Vanguard Group Inc. Raises Stake in CareDx, Inc (NASDAQ:CDNA)

Vanguard Group Inc. raised its position in shares of CareDx, Inc (NASDAQ:CDNA) by 1.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,138,591 shares of the company’s stock after purchasing an additional 50,667 shares during the quarter. Vanguard Group Inc. owned 7.65% of CareDx worth $28,970,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Kent Lake Capital LLC purchased a new position in shares of CareDx in the third quarter worth $9,628,000. State Street Corp lifted its holdings in shares of CareDx by 38.6% in the second quarter. State Street Corp now owns 4,214,680 shares of the company’s stock worth $90,531,000 after buying an additional 1,174,094 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of CareDx by 24.6% in the second quarter. BlackRock Inc. now owns 5,439,512 shares of the company’s stock worth $46,236,000 after buying an additional 1,074,531 shares in the last quarter. Bellevue Group AG lifted its holdings in shares of CareDx by 57.6% in the first quarter. Bellevue Group AG now owns 2,311,176 shares of the company’s stock worth $85,490,000 after buying an additional 844,624 shares in the last quarter. Finally, Armistice Capital LLC purchased a new position in shares of CareDx in the fourth quarter worth $5,705,000.

CareDx Stock Performance

CDNA stock opened at $9.14 on Friday. CareDx, Inc has a one year low of $4.80 and a one year high of $12.93. The company’s fifty day moving average price is $9.73 and its 200-day moving average price is $9.12. The company has a market capitalization of $473.26 million, a PE ratio of -2.58 and a beta of 1.42.

CareDx (NASDAQ:CDNA) last released its earnings results on Wednesday, February 28th. The company reported ($2.21) EPS for the quarter, missing the consensus estimate of ($0.24) by ($1.97). CareDx had a negative return on equity of 51.40% and a negative net margin of 67.88%. The company had revenue of $65.57 million during the quarter, compared to analysts’ expectations of $63.66 million. During the same period last year, the firm posted ($0.34) EPS. CareDx’s quarterly revenue was down 20.4% compared to the same quarter last year. On average, research analysts predict that CareDx, Inc will post -1.59 EPS for the current fiscal year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.